ATTORNEY GENERAL BRIDGET HILL URGES CONSUMERS TO CHECK ELIGIBILITY FOR COMPENSATION FOR INFLATED GENERIC DRUG PRICES

Attorney General Bridget Hill Joins 50 States and Territories Filing Motion for Preliminary Approval for $39.1 Million Settlement with Generic Drug Manufacturer Apotex over Conspiracy to Inflate Prices and Limit Competition

(Cheyenne, Wyoming) – Attorney General Bridget Hill is urging consumers to check their eligibility for compensation for certain generic drug purchases as Wyoming joins 50 states and territories in seeking preliminary approval for a $39.1 million settlement with generic drug manufacturer Apotex over conspiracy to inflate prices and limit competition.

Attorney General Hill and the multistate coalition previously announced the settlement in principle with Apotex last fall along with a $10 million settlement with Heritage Pharmaceuticals. At the time of that announcement, the settlement with Apotex was conditioned on the signatures of all necessary states and territories. Those signatures have been obtained, and the coalition is filing the settlement in U.S. District Court for the District of Connecticut in Hartford.

If you purchased a generic prescription drug from either Heritage or Apotex between 2010 and 2018, you may be eligible for compensation. To determine your eligibility, call 1-866-290-0182 (Toll-Free), email info@AGGenericDrugs.com or visit www.AGGenericDrugs.com. This website includes a list of generic drugs which are involved in these settlements. The website also includes the option to opt out of the settlements.

The settlement agreements resolve allegations that both Apotex and Heritage engaged in widespread, long-running conspiracies to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade with regard to numerous generic prescription drugs. As part of the settlement agreements, both Apotex and Heritage have agreed to cooperate in the ongoing multistate litigations. Both companies have further agreed to a series of internal reforms to ensure fair competition and compliance with antitrust laws.